N-(2,5-Difluoro-phenyl)-2,2-dimethyl-propionamide | 130721-82-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,5-Difluoro-phenyl)-2,2-dimethyl-propionamide
• 英文别名: N-(2,5-difluorophenyl)-2,2-dimethylpropanamide
• CAS: 130721-82-3
• 化学式: C₁₁H₁₃F₂NO
• mdl: MFCD20538501
• 分子量: 213.227
• InChiKey: LCQIOCAPKVHITR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2,5-Difluoro-phenyl)-2,2-dimethyl-propionamide 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 乙二醇二甲醚 为溶剂， 反应 3.5h， 生成 1-(2-Amino-3,6-difluoro-phenyl)-2,2,2-trifluoro-ethanone
  参考文献：
  名称：

  Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors

  摘要：

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00486-2
• 作为产物：
  描述：

  2,5-二氟苯胺 、 三甲基乙酰氯 在 TEA 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-(2,5-Difluoro-phenyl)-2,2-dimethyl-propionamide
  参考文献：
  名称：

  Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors

  摘要：

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00486-2

文献信息

• Reavill, David R.; Richardson, Stewart K., Synthetic Communications, 1990, vol. 20, # 10, p. 1423 - 1436
  作者：Reavill, David R.、Richardson, Stewart K.

  DOI：——

  日期：——
• REAVILL, DAVID R.;RICHARDSON, STEWART K., SYNTH. COMMUN., 20,(1990) N0, C. 1423-1436
  作者：REAVILL, DAVID R.、RICHARDSON, STEWART K.

  DOI：——

  日期：——
• US7342016B2
  申请人：——

  公开号：US7342016B2

  公开（公告）日：2008-03-11
• Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors
  作者：Mona Patel、Soo S. Ko、Robert J. McHugh、Jay A. Markwalder、Anurag S. Srivastava、Beverly C. Cordova、Ronald M. Klabe、Susan Erickson-Viitanen、George L. Trainor、Steven.P. Seitz

  DOI：10.1016/s0960-894x(99)00486-2

  日期：1999.10

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.